Skip to main content
PMC home page
British Journal of Cancer logoLink to British Journal of Cancer
. 1999 Nov;81(5):774–782. doi: 10.1038/sj.bjc.6690763

Matrix metalloproteinases in human melanoma cell lines and xenografts: increased expression of activated matrix metalloproteinase-2 (MMP-2) correlates with melanoma progression

U B Hofmann 1,3, J R Westphal 1, E T Waas 2, A J W Zendman 1, I M H A Cornelissen 1, D J Ruiter 1, G N P van Muijen 1
PMCID: PMC2374291  PMID: 10555745

Abstract

Matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) are involved in tumour progression and metastasis. In this study, we investigated the in vitro and in vivo expression patterns of MMP-1, MMP-2, MMP-3, MMP-9, TIMP-1 and TIMP-2 mRNA and protein in a previously described human melanoma xenograft model. This model consists of eight human melanoma cell lines with different metastatic behaviour after subcutaneous (s.c.) injection into nude mice. MMP-1 mRNA was detectable in all cell lines by reverse transcription polymerase chain reaction (RT-PCR), but the expression was too low to be detected by Northern blot analysis. No MMP-1 protein could be found using Western blotting. MMP-2 mRNA and protein were present in all cell lines, with the highest expression of both latent and active MMP-2 in the highest metastatic cell lines MV3 and BLM. MMP-3 mRNA was expressed in MV3 and BLM, and in the non-metastatic cell line 530, whereas MMP-3 protein was detectable only in MV3 and BLM. None of the melanoma cell lines expressed MMP-9. TIMP-1 and TIMP-2 mRNA and protein, finally, were present in all cell lines. A correlation between TIMP expression level and metastatic capacity of cell lines, however, was lacking. MMP and TIMP mRNA and protein expression levels were also studied in s.c. xenograft lesions derived from a selection of these cell lines. RT-PCR analysis revealed that MMP-1 mRNA was present in MV3 and BLM xenografts, and to a lesser extent in 530. Positive staining for MMP-1 protein was found in xenograft lesions derived from both low and high metastatic cell lines, indicating an in vivo up-regulation of MMP-1. MMP-2 mRNA was detectable only in xenografts derived from the highly metastatic cell lines 1F6m, MV3 and BLM. In agreement with the in vitro results, the highest levels of both latent and activated MMP-2 protein were observed in MV3 and BLM xenografts. With the exception of MMP-9 mRNA expression in 530 xenografts, MMP-3, MMP-9, and TIMP-1 mRNA and protein were not detectable in any xenograft, indicating a down-regulated expression of MMP-3 and TIMP-1 in vivo. TIMP-2 mRNA and protein were present in all xenografts; interestingly, the strongest immunoreactivity of tumour cells was found at the border of necrotic areas. Our study demonstrates that of all tested components of the matrix metalloproteinase system, only expression of activated MMP-2 correlates with increased malignancy in our melanoma xenograft model, corroborating an important role of MMP-2 in human melanoma invasion and metastasis. © 1999 Cancer Research Campaign

Keywords: matrix metalloproteinase (MMP), tissue inhibitor of matrix metalloproteinases (TIMP), melanoma, xenograft, invasion, metastasis

Full Text

The Full Text of this article is available as a PDF (387.2 KB).

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Ahonen M., Baker A. H., Kähäri V. M. Adenovirus-mediated gene delivery of tissue inhibitor of metalloproteinases-3 inhibits invasion and induces apoptosis in melanoma cells. Cancer Res. 1998 Jun 1;58(11):2310–2315. [PubMed] [Google Scholar]
  2. Butler G. S., Butler M. J., Atkinson S. J., Will H., Tamura T., Schade van Westrum S., Crabbe T., Clements J., d'Ortho M. P., Murphy G. The TIMP2 membrane type 1 metalloproteinase "receptor" regulates the concentration and efficient activation of progelatinase A. A kinetic study. J Biol Chem. 1998 Jan 9;273(2):871–880. doi: 10.1074/jbc.273.2.871. [DOI] [PubMed] [Google Scholar]
  3. Chambers A. F., Matrisian L. M. Changing views of the role of matrix metalloproteinases in metastasis. J Natl Cancer Inst. 1997 Sep 3;89(17):1260–1270. doi: 10.1093/jnci/89.17.1260. [DOI] [PubMed] [Google Scholar]
  4. Coussens L. M., Werb Z. Matrix metalloproteinases and the development of cancer. Chem Biol. 1996 Nov;3(11):895–904. doi: 10.1016/s1074-5521(96)90178-7. [DOI] [PubMed] [Google Scholar]
  5. Durko M., Navab R., Shibata H. R., Brodt P. Suppression of basement membrane type IV collagen degradation and cell invasion in human melanoma cells expressing an antisense RNA for MMP-1. Biochim Biophys Acta. 1997 May 27;1356(3):271–280. doi: 10.1016/s0167-4889(97)00004-9. [DOI] [PubMed] [Google Scholar]
  6. Ferrier C. M., van Geloof W. L., de Witte H. H., Kramer M. D., Ruiter D. J., van Muijen G. N. Epitopes of components of the plasminogen activation system are re-exposed in formalin-fixed paraffin sections by different retrieval techniques. J Histochem Cytochem. 1998 Apr;46(4):469–476. doi: 10.1177/002215549804600406. [DOI] [PubMed] [Google Scholar]
  7. Gomez D. E., Alonso D. F., Yoshiji H., Thorgeirsson U. P. Tissue inhibitors of metalloproteinases: structure, regulation and biological functions. Eur J Cell Biol. 1997 Oct;74(2):111–122. [PubMed] [Google Scholar]
  8. Grant G. M., Cobb J. K., Castillo B., Klebe R. J. Regulation of matrix metalloproteinases following cellular transformation. J Cell Physiol. 1996 Apr;167(1):177–183. doi: 10.1002/(SICI)1097-4652(199604)167:1<177::AID-JCP21>3.0.CO;2-7. [DOI] [PubMed] [Google Scholar]
  9. Heppner K. J., Matrisian L. M., Jensen R. A., Rodgers W. H. Expression of most matrix metalloproteinase family members in breast cancer represents a tumor-induced host response. Am J Pathol. 1996 Jul;149(1):273–282. [PMC free article] [PubMed] [Google Scholar]
  10. Imren S., Kohn D. B., Shimada H., Blavier L., DeClerck Y. A. Overexpression of tissue inhibitor of metalloproteinases-2 retroviral-mediated gene transfer in vivo inhibits tumor growth and invasion. Cancer Res. 1996 Jul 1;56(13):2891–2895. [PubMed] [Google Scholar]
  11. Kanayama H., Yokota K., Kurokawa Y., Murakami Y., Nishitani M., Kagawa S. Prognostic values of matrix metalloproteinase-2 and tissue inhibitor of metalloproteinase-2 expression in bladder cancer. Cancer. 1998 Apr 1;82(7):1359–1366. [PubMed] [Google Scholar]
  12. Khokha R. Suppression of the tumorigenic and metastatic abilities of murine B16-F10 melanoma cells in vivo by the overexpression of the tissue inhibitor of the metalloproteinases-1. J Natl Cancer Inst. 1994 Feb 16;86(4):299–304. doi: 10.1093/jnci/86.4.299. [DOI] [PubMed] [Google Scholar]
  13. Khokha R., Zimmer M. J., Wilson S. M., Chambers A. F. Up-regulation of TIMP-1 expression in B16-F10 melanoma cells suppresses their metastatic ability in chick embryo. Clin Exp Metastasis. 1992 Nov;10(6):365–370. doi: 10.1007/BF00133464. [DOI] [PubMed] [Google Scholar]
  14. Lampert K., Machein U., Machein M. R., Conca W., Peter H. H., Volk B. Expression of matrix metalloproteinases and their tissue inhibitors in human brain tumors. Am J Pathol. 1998 Aug;153(2):429–437. doi: 10.1016/S0002-9440(10)65586-1. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. MacDougall J. R., Bani M. R., Lin Y., Rak J., Kerbel R. S. The 92-kDa gelatinase B is expressed by advanced stage melanoma cells: suppression by somatic cell hybridization with early stage melanoma cells. Cancer Res. 1995 Sep 15;55(18):4174–4181. [PubMed] [Google Scholar]
  16. MacDougall J. R., Matrisian L. M. Contributions of tumor and stromal matrix metalloproteinases to tumor progression, invasion and metastasis. Cancer Metastasis Rev. 1995 Dec;14(4):351–362. doi: 10.1007/BF00690603. [DOI] [PubMed] [Google Scholar]
  17. Montgomery A. M., Mueller B. M., Reisfeld R. A., Taylor S. M., DeClerck Y. A. Effect of tissue inhibitor of the matrix metalloproteinases-2 expression on the growth and spontaneous metastasis of a human melanoma cell line. Cancer Res. 1994 Oct 15;54(20):5467–5473. [PubMed] [Google Scholar]
  18. Mueller B. M. Different roles for plasminogen activators and metalloproteinases in melanoma metastasis. Curr Top Microbiol Immunol. 1996;213(Pt 1):65–80. doi: 10.1007/978-3-642-61107-0_5. [DOI] [PubMed] [Google Scholar]
  19. Nagase H. Activation mechanisms of matrix metalloproteinases. Biol Chem. 1997 Mar-Apr;378(3-4):151–160. [PubMed] [Google Scholar]
  20. Nakahara H., Howard L., Thompson E. W., Sato H., Seiki M., Yeh Y., Chen W. T. Transmembrane/cytoplasmic domain-mediated membrane type 1-matrix metalloprotease docking to invadopodia is required for cell invasion. Proc Natl Acad Sci U S A. 1997 Jul 22;94(15):7959–7964. doi: 10.1073/pnas.94.15.7959. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Newell K. J., Witty J. P., Rodgers W. H., Matrisian L. M. Expression and localization of matrix-degrading metalloproteinases during colorectal tumorigenesis. Mol Carcinog. 1994 Aug;10(4):199–206. doi: 10.1002/mc.2940100404. [DOI] [PubMed] [Google Scholar]
  22. Nielsen B. S., Timshel S., Kjeldsen L., Sehested M., Pyke C., Borregaard N., Danø K. 92 kDa type IV collagenase (MMP-9) is expressed in neutrophils and macrophages but not in malignant epithelial cells in human colon cancer. Int J Cancer. 1996 Jan 3;65(1):57–62. doi: 10.1002/(SICI)1097-0215(19960103)65:1<57::AID-IJC10>3.0.CO;2-F. [DOI] [PubMed] [Google Scholar]
  23. Nomura H., Sato H., Seiki M., Mai M., Okada Y. Expression of membrane-type matrix metalloproteinase in human gastric carcinomas. Cancer Res. 1995 Aug 1;55(15):3263–3266. [PubMed] [Google Scholar]
  24. Ray J. M., Stetler-Stevenson W. G. Gelatinase A activity directly modulates melanoma cell adhesion and spreading. EMBO J. 1995 Mar 1;14(5):908–917. doi: 10.1002/j.1460-2075.1995.tb07072.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  25. Sato H., Takino T., Okada Y., Cao J., Shinagawa A., Yamamoto E., Seiki M. A matrix metalloproteinase expressed on the surface of invasive tumour cells. Nature. 1994 Jul 7;370(6484):61–65. doi: 10.1038/370061a0. [DOI] [PubMed] [Google Scholar]
  26. Sreenath T., Matrisian L. M., Stetler-Stevenson W., Gattoni-Celli S., Pozzatti R. O. Expression of matrix metalloproteinase genes in transformed rat cell lines of high and low metastatic potential. Cancer Res. 1992 Sep 15;52(18):4942–4947. [PubMed] [Google Scholar]
  27. Stetler-Stevenson W. G., Aznavoorian S., Liotta L. A. Tumor cell interactions with the extracellular matrix during invasion and metastasis. Annu Rev Cell Biol. 1993;9:541–573. doi: 10.1146/annurev.cb.09.110193.002545. [DOI] [PubMed] [Google Scholar]
  28. Strongin A. Y., Collier I., Bannikov G., Marmer B. L., Grant G. A., Goldberg G. I. Mechanism of cell surface activation of 72-kDa type IV collagenase. Isolation of the activated form of the membrane metalloprotease. J Biol Chem. 1995 Mar 10;270(10):5331–5338. doi: 10.1074/jbc.270.10.5331. [DOI] [PubMed] [Google Scholar]
  29. Sugiura Y., Shimada H., Seeger R. C., Laug W. E., DeClerck Y. A. Matrix metalloproteinases-2 and -9 are expressed in human neuroblastoma: contribution of stromal cells to their production and correlation with metastasis. Cancer Res. 1998 May 15;58(10):2209–2216. [PubMed] [Google Scholar]
  30. Tokuraku M., Sato H., Murakami S., Okada Y., Watanabe Y., Seiki M. Activation of the precursor of gelatinase A/72 kDa type IV collagenase/MMP-2 in lung carcinomas correlates with the expression of membrane-type matrix metalloproteinase (MT-MMP) and with lymph node metastasis. Int J Cancer. 1995 Oct 20;64(5):355–359. doi: 10.1002/ijc.2910640513. [DOI] [PubMed] [Google Scholar]
  31. Valente P., Fassina G., Melchiori A., Masiello L., Cilli M., Vacca A., Onisto M., Santi L., Stetler-Stevenson W. G., Albini A. TIMP-2 over-expression reduces invasion and angiogenesis and protects B16F10 melanoma cells from apoptosis. Int J Cancer. 1998 Jan 19;75(2):246–253. doi: 10.1002/(sici)1097-0215(19980119)75:2<246::aid-ijc13>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
  32. Van Muijen G. N., Cornelissen L. M., Jansen C. F., Figdor C. G., Johnson J. P., Bröcker E. B., Ruiter D. J. Antigen expression of metastasizing and non-metastasizing human melanoma cells xenografted into nude mice. Clin Exp Metastasis. 1991 May-Jun;9(3):259–272. doi: 10.1007/BF01753729. [DOI] [PubMed] [Google Scholar]
  33. Väisänen A., Kallioinen M., Taskinen P. J., Turpeenniemi-Hujanen T. Prognostic value of MMP-2 immunoreactive protein (72 kD type IV collagenase) in primary skin melanoma. J Pathol. 1998 Sep;186(1):51–58. doi: 10.1002/(SICI)1096-9896(199809)186:1<51::AID-PATH131>3.0.CO;2-P. [DOI] [PubMed] [Google Scholar]
  34. Väisänen A., Tuominen H., Kallioinen M., Turpeenniemi-Hujanen T. Matrix metalloproteinase-2 (72 kD type IV collagenase) expression occurs in the early stage of human melanocytic tumour progression and may have prognostic value. J Pathol. 1996 Nov;180(3):283–289. doi: 10.1002/(SICI)1096-9896(199611)180:3<283::AID-PATH662>3.0.CO;2-3. [DOI] [PubMed] [Google Scholar]
  35. Westphal J. R., van't Hullenaar R. G., van der Laak J. A., Cornelissen I. M., Schalkwijk L. J., van Muijen G. N., Wesseling P., de Wilde P. C., Ruiter D. J., de Waal R. M. Vascular density in melanoma xenografts correlates with vascular permeability factor expression but not with metastatic potential. Br J Cancer. 1997;76(5):561–570. doi: 10.1038/bjc.1997.427. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Woolley D. E., Grafton C. A. Collagenase immunolocalization studies of cutaneous secondary melanomas. Br J Cancer. 1980 Aug;42(2):260–265. doi: 10.1038/bjc.1980.225. [DOI] [PMC free article] [PubMed] [Google Scholar]
  37. Yamamoto M., Mohanam S., Sawaya R., Fuller G. N., Seiki M., Sato H., Gokaslan Z. L., Liotta L. A., Nicolson G. L., Rao J. S. Differential expression of membrane-type matrix metalloproteinase and its correlation with gelatinase A activation in human malignant brain tumors in vivo and in vitro. Cancer Res. 1996 Jan 15;56(2):384–392. [PubMed] [Google Scholar]
  38. Zucker S., Drews M., Conner C., Foda H. D., DeClerck Y. A., Langley K. E., Bahou W. F., Docherty A. J., Cao J. Tissue inhibitor of metalloproteinase-2 (TIMP-2) binds to the catalytic domain of the cell surface receptor, membrane type 1-matrix metalloproteinase 1 (MT1-MMP). J Biol Chem. 1998 Jan 9;273(2):1216–1222. doi: 10.1074/jbc.273.2.1216. [DOI] [PubMed] [Google Scholar]
  39. van Muijen G. N., Jansen K. F., Cornelissen I. M., Smeets D. F., Beck J. L., Ruiter D. J. Establishment and characterization of a human melanoma cell line (MV3) which is highly metastatic in nude mice. Int J Cancer. 1991 Apr 22;48(1):85–91. doi: 10.1002/ijc.2910480116. [DOI] [PubMed] [Google Scholar]
  40. van den Oord J. J., Paemen L., Opdenakker G., de Wolf-Peeters C. Expression of gelatinase B and the extracellular matrix metalloproteinase inducer EMMPRIN in benign and malignant pigment cell lesions of the skin. Am J Pathol. 1997 Sep;151(3):665–670. [PMC free article] [PubMed] [Google Scholar]

Articles from British Journal of Cancer are provided here courtesy of Cancer Research UK

RESOURCES